Paris (France), February 6, 2023 – 7:30 p.m. CET – Onxeo SA (Euronext Growth Paris: ALONX), hereinafter “Onxeo” or “the Company”, a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA damage response mechanisms (DDR) and pilot oncogenes, announces that the extraordinary general meeting (AGE) held today at 2 p.m. was able to validly deliberate with a quorum of 44.35%.
The EGM adopted all the resolutions approved by the Board of Directors.
The result of the votes by resolution and the minutes of the meeting will be available within the legal deadlines on the Company’s website, in the General Meetings section.
To receive all of ONXEO’s financial information in real time, send a request by email to [email protected]. Your registration will be immediate.